文献速递炎症性肠病

炎症性肠病中生物制剂与口服小分子药物严重感染风险的比较:系统综述与Meta分析

Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-08-06

该系统综述与Meta分析纳入20项头对头研究,比较炎症性肠病患者使用不同 advanced therapies 的严重感染风险。维得利珠单抗在溃疡性结肠炎中严重感染风险低于TNFα拮抗剂,但在克罗恩病中无此差异;乌司奴单抗在克罗恩病中严重感染风险低于TNFα拮抗剂和维得利珠单抗。

要点

  • 溃疡性结肠炎患者中,维得利珠单抗较TNFα拮抗剂严重感染风险更低(OR 0.68)。
  • 克罗恩病患者中,乌司奴单抗较TNFα拮抗剂严重感染风险更低(OR 0.49)。
  • 克罗恩病患者中,乌司奴单抗较维得利珠单抗严重感染风险更低(OR 0.40)。

核心结论

  • 维得利珠单抗在溃疡性结肠炎患者中可能较TNFα拮抗剂提供净获益,但在克罗恩病患者中未显示此获益。
  • 乌司奴单抗在克罗恩病患者中可能较TNFα拮抗剂和维得利珠单抗提供净获益。

研究设计与样本

  • 系统综述与Meta分析,检索截至2022年2月28日,纳入20项头对头研究,比较TNFα拮抗剂、维得利珠单抗、乌司奴单抗、托法替布、非戈替尼和奥扎尼莫德在炎症性肠病患者中的严重感染风险。

主要发现

  • 所有炎症性肠病患者中,维得利珠单抗与TNFα拮抗剂严重感染风险无显著差异(17个队列:OR 0.84,95%CI 0.68-1.04;异质性I²=37%)。
  • 溃疡性结肠炎患者中,维得利珠单抗与TNFα拮抗剂相比严重感染风险更低(11个队列:OR 0.68,95%CI 0.56-0.83;I²=0%)。
  • 克罗恩病患者中,维得利珠单抗与TNFα拮抗剂严重感染风险无显著差异(9个队列:OR 1.03,95%CI 0.78-1.35;I²=42%)。
  • 克罗恩病患者中,乌司奴单抗与TNFα拮抗剂相比严重感染风险更低(3个队列:OR 0.49,95%CI 0.25-0.93;I²=16%)。
  • 克罗恩病患者中,乌司奴单抗与维得利珠单抗相比严重感染风险更低(3个队列:OR 0.40,95%CI 0.17-0.93;I²=67%)。

关键数值与推荐

  • 年龄、性别、既往生物制剂暴露和生物制剂单药治疗未影响维得利珠单抗与TNFα拮抗剂严重感染风险的关联。
  • 比较其他 advanced therapies 的研究较少。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Safety is a key consideration when choosing advanced therapies (biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory bowel diseases (IBDs). We performed a systematic review and meta-analysis comparing the risk of serious infections with advanced therapies in active comparator studies. METHODS: Through a systematic search until February 28, 2022, we included 20 head-to-head studies comparing risk of serious infections with tumor necrosis factor α (TNFα) antagonists, vedolizumab, ustekinumab, tofacitinib, filgotinib, and ozanimod in patients with IBD. We performed random-effects meta-analysis comparing different advanced therapies. RESULTS: No significant difference was observed in the risk of serious infections between vedolizumab vs TNFα antagonists in all patients with IBD (17 cohorts: odds ratio [OR], 0.84; 95% CI, 0.68-1.04), with moderate heterogeneity (I2 = 37%); on subgroup analysis, vedolizumab was associated with a lower risk of serious infections in patients with ulcerative colitis (11 cohorts: OR, 0.68; 95% CI, 0.56-0.83; I2 = 0%), but not in Crohn's disease (CD) (9 cohorts: OR, 1.03; 95% CI, 0.78-1.35; I2 = 42%). Age, sex, prior biologic exposure, and use of biologic monotherapy did not influence this association. In patients with CD, ustekinumab was associated with a lower risk of serious infections vs TNFα antagonists (3 cohorts: OR, 0.49; 95% CI, 0.25-0.93; I2 = 16%) and vs vedolizumab (3 cohorts: OR, 0.40; 95% CI, 0.17-0.93; I2 = 67%). Few studies compared other advanced therapies. CONCLUSIONS: Vedolizumab may offer net benefit over TNFα antagonists in patients with ulcerative colitis, but not in CD. Ustekinumab may offer net benefit over TNFα antagonists and vedolizumab in patients with CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Solitano V, Facciorusso A, Jess T, et al. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022. PMID: 35944832. doi:10.1016/j.cgh.2022.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。